Literature DB >> 2137718

Dopamine uptake inhibitory capacities of beta-carboline and 3,4-dihydro-beta-carboline analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) oxidation products.

G Drucker1, K Raikoff, E J Neafsey, M A Collins.   

Abstract

Potentially endogenous beta-carboline and 3,4-dihydro-beta-carboline alkaloidal compounds were compared, generally as 2-methylated (quaternary) and normethylated pairs, to the neurotoxin, 1-methyl-4-phenyl-dihydropyridinium ion (MPP+), with respect to inhibition of [3H]dopamine uptake into rat striatal synaptosomal preparations. Although less potent than MPP+, several compounds displayed IC50 values for inhibition in the moderate range (12-24 microM). Notably, quaternization generally did not improve inhibitory potency, and the 3,4-dihydro-compounds often were more effective inhibitors than their heteroaromatic analogs. The partially competitive nature of inhibition by one of the more effective pairs, 2-methyl-harmine and harmine, was consistent with uptake of the beta-carbolines by the synaptosomal dopamine uptake system, as was the fact that the accumulation of 2-[14C]methyl-harmine was significantly reduced by low Na+ media and by nomifensine, a potent inhibitor of the dopamine transporter. When viewed with reports that certain 2-methyl-beta-carbolines show MPP+-like toxicity in vitro and in vivo, these studies support the proposal that a mammalian beta-carbolinium compound may be taken up by nigrostriatal neurons and provoke the neuronal degeneration underlying Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2137718     DOI: 10.1016/0006-8993(90)90318-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  11 in total

Review 1.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Characterization of brain beta-carboline-2-N-methyltransferase, an enzyme that may play a role in idiopathic Parkinson's disease.

Authors:  D A Gearhart; E J Neafsey; M A Collins
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

3.  Neuropharmacological characterization of local ibogaine effects on dopamine release.

Authors:  M S Reid; K Hsu; K H Souza; P A Broderick; S P Berger
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 4.  Bioenergetics and metabolism: a bench to bedside perspective.

Authors:  Russell H Swerdlow
Journal:  J Neurochem       Date:  2016-03-10       Impact factor: 5.372

5.  Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine.

Authors:  R Albores; E J Neafsey; G Drucker; J Z Fields; M A Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 6.  Does mitochondrial DNA play a role in Parkinson's disease? A review of cybrid and other supportive evidence.

Authors:  Russell H Swerdlow
Journal:  Antioxid Redox Signal       Date:  2011-05-25       Impact factor: 8.401

7.  Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.

Authors:  A Ostergren; A Fredriksson; E B Brittebo
Journal:  J Neural Transm (Vienna)       Date:  2005-08-03       Impact factor: 3.575

8.  Neuromelanin Modulates Heterocyclic Aromatic Amine-Induced Dopaminergic Neurotoxicity.

Authors:  Vivek Lawana; Se Young Um; Jean-Christophe Rochet; Robert J Turesky; Jonathan H Shannahan; Jason R Cannon
Journal:  Toxicol Sci       Date:  2020-01-01       Impact factor: 4.849

9.  α-Carboline derivative TJY-16 inhibits tumor growth by inducing G2/M cell cycle arrest in glioma cells.

Authors:  Hsiao-Chieh Huang; Wei-Ting Liu; Kuo-Su Hua; Hui-Chi Hung; Jui-Ying Tsai; Sheng-Chu Kuo; Li-Jiau Huang; Po-Wu Gean
Journal:  J Biomed Sci       Date:  2016-01-19       Impact factor: 8.410

Review 10.  Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.

Authors:  Jonathan Hamill; Jaime Hallak; Serdar M Dursun; Glen Baker
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.